Metoprolol

also known as Metoprolol succinate · metoprolol tartrate · TOPROL-XL · Betaloc ZOK · MET · betaloc · Lopressor · metoprolol CR/XL · +18 more

Other / unclassified targets ADRB1 via inhibition

Developed for: hypertensive disorder · atrial fibrillation · coronary artery disorder · heart failure · essential hypertension · type 2 diabetes mellitus · breast cancer · cardiac rhythm disease
+57 more
· chronic obstructive pulmonary disease · diastolic heart failure · heart disorder · ST-elevation myocardial infarction · symptomatic heart failure · acquired hypothalamic obesity · cardiovascular disorder · chronic kidney disease · cirrhosis of liver · congestive heart failure · myocardial infarction · Prader-Willi syndrome · acute coronary syndrome · acute myocardial infarction · atherosclerosis · atrial flutter · diabetes mellitus · dilated cardiomyopathy · Duchenne muscular dystrophy · gastric cancer · heart valve disorder · hypertrophic cardiomyopathy · interstitial cystitis · intracranial arteriosclerosis · intrinsic cardiomyopathy · mitral valve insufficiency · mitral valve prolapse · myocardial ischemia · myofascial pain syndrome · nephrosclerosis · obstructive sleep apnea syndrome · peripheral arterial disease · pulmonary immaturity · strictly posterior acute myocardial infarction · subarachnoid hemorrhage · syncope, familial vasovagal · systolic heart failure · acute respiratory distress syndrome · aortic valve insufficiency · aortic valve stenosis · beta thalassemia · cardiac arrest · cardiogenic shock · cardiomyopathy · cirrhotic cardiomyopathy · diabetic macular edema · end stage renal failure · infectious disease with sepsis · metabolic syndrome X · migraine disorder · mitral valve stenosis · non-familial dilated cardiomyopathy · postural orthostatic tachycardia syndrome · sudden cardiac arrest · Tako-tsubo cardiomyopathy · ventricular fibrillation · ventricular tachycardia
Investigated by: AstraZeneca · Saniona · National Heart, Lung, and Blood Institute (NHLBI) · Forest Laboratories · Sanofi · Boehringer Ingelheim
+153 more
· Bristol-Myers Squibb · Mayo Clinic · Weill Medical College of Cornell University · AbbVie · Bispebjerg Hospital · Creighton University · Danish Heart Foundation · Eli Lilly and Company · GlaxoSmithKline · National Institute of General Medical Sciences (NIGMS) · National Institute on Aging (NIA) · Tehran University of Medical Sciences · The Third Xiangya Hospital of Central South University · University Hospital, Basel, Switzerland · University of Oslo · University of Texas Southwestern Medical Center · University of Wisconsin, Madison · Uppsala University · ViiV Healthcare · Wake Forest University Health Sciences · Washington University School of Medicine · Aalborg University Hospital · Aarhus University Hospital · Abant Izzet Baysal University · Abbott Medical Devices · Ajou University School of Medicine · Amager Hospital · American Heart Association · Amgen · Astellas Pharma Inc · Bayside Health · Beijing Chao Yang Hospital · Bornholm Hospital · Boston University · British Heart Foundation · CAMC Health System · Canadian Institutes of Health Research (CIHR) · Case Western Reserve University · Chinese PLA General Hospital · Col. Suthee Panichkul · Corcept Therapeutics · Cornell University · Duke Clinical Research Institute · East Coast Institute for Research · Endeavor Health · First Affiliated Hospital of Chongqing Medical University · First Affiliated Hospital of Harbin Medical University · Fujian Provincial Hospital · Galderma R&D · Gentofte Hospital · Genzyme, a Sanofi Company · Gilead Sciences · Glostrup University Hospital, Copenhagen · Gothia Forum - Center for Clinical Trial · Göteborg University · Gødstrup Hospital · Hackensack Meridian Health · Hamilton Health Sciences Corporation · Harbin Medical University · Herlev Hospital · Holbaek Hospital · Hospital of Southern Jutland · Hospitalsenheden Midt · Hospitalsenheden Vest · Hvidovre University Hospital · Institute of Application-oriented Research and Clinical Trials GmbH · Isfahan University of Medical Sciences · Janssen Research & Development, LLC · Johns Hopkins University · Karolinska Institutet · Kuopio University Hospital · LEO Pharma · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Maastricht University Medical Center · all 159 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (3)	US (FDA)	TOPROL-XL	—	2001-02-05 – 2007-07-18	fda.gov ↗
Label expansions (3)	US (FDA)	LOPRESSOR	—	1983-04-12 – 1986-06-27	fda.gov ↗
Approved	US (FDA)	LOPRESSOR	—	1978-08-07	fda.gov ↗

Trials 134 · started per year

today

US approved 1978

1978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT05891119	Jun 2023 → Aug 2024	atopic eczema	Amgen	Completed	No outcome recorded
Phase 0	NCT05096884	Mar 2022 → Sep 2023	COVID-19, cardiac rhythm disease	Hackensack Meridian Health	Terminated	No outcome recorded
Phase 0	NCT02025348	Jan → Mar 2014	—	AstraZeneca	Completed	No outcome recorded
Phase 131 trials
Phase 1	NCT06808802	Feb → Apr 2025	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT06686628	Nov 2024 → Nov 2025	atopic eczema	Sanofi	Completed	No outcome recorded
Phase 1	NCT05745337	Feb → Dec 2023	atrial fibrillation, diastolic heart failure	University of Vermont	Unknown	No outcome recorded
Phase 1	NCT04425902	Dec 2020 → Mar 2021	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT04504045	Sep 2020 → May 2022	type 2 diabetes mellitus	University of Southern Denmark	Terminated	No outcome recorded
Phase 1	NCT04254783	May 2020 → Oct 2022	Crohn disease, ulcerative colitis	AbbVie	Completed	No outcome recorded
Phase 1	NCT03556592	Aug 2018 → Mar 2020	atopic eczema	LEO Pharma	Completed	No outcome recorded
Phase 1	NCT03488719	Jul 2018 → Jun 2019	—	Saniona	Completed	No outcome recorded
Phase 1	NCT03457597	Mar → Apr 2018	—	Corcept Therapeutics	Completed	No outcome recorded
Phase 1	NCT03441412	Feb → Mar 2018	—	Vastra Gotaland Region	Completed	No outcome recorded
Phase 1	NCT03286829	Dec 2017 → Feb 2018	—	Saniona	Completed	No outcome recorded
Phase 1	NCT03103568	Mar → Jun 2017	—	Swedish Orphan Biovitrum	Completed	No outcome recorded
Phase 1	NCT02940379	Oct → Dec 2016	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT02772601	Sep 2016 → Jun 2017	psoriasis	AbbVie	Completed	No outcome recorded
Phase 1	NCT02647086	Dec 2015 → Jul 2016	atopic eczema	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02578277	Nov → Dec 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT02361619	Feb 2015 → Sep 2016	—	Turku University Hospital	Completed	No outcome recorded
Phase 1	NCT02254148	Oct → Dec 2014	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02045966	Feb → Apr 2014	hepatitis C virus infection	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02097511	Dec 2013 → Jan 2014	hypertensive disorder, peripheral arterial disease	Ajou University School of Medicine	Completed	No outcome recorded
Phase 1	NCT01902550	Jul → Oct 2013	—	Janssen Research & Development, LLC	Withdrawn	No outcome recorded
Phase 1	NCT01585623	Jun 2012 → Mar 2013	cancer	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01659944	May → Jun 2012	—	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 1	NCT01386593	May 2011 → Jan 2012	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT01324388	Mar → Aug 2011	type 2 diabetes mellitus	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT01211821	Sep → Nov 2010	atrial fibrillation	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01845194	Dec 2009 → Oct 2013	mitochondrial membrane transport disorder	Institute of Application-oriented Research and Clinical Trials GmbH	Completed	No outcome recorded
Phase 1	NCT00700947	Oct 2007 → Jun 2009	mitral valve insufficiency	Wake Forest University Health Sciences	Terminated	No outcome recorded
Phase 1	NCT00648271	Dec 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT01478490	Sep → Nov 2002	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT04082910	Sep 2019 → Dec 2022	cancer, hematopoietic and lymphoid cell neoplasm	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 1/2	NCT03361280	Feb 2015 → Mar 2016	chronic kidney disease	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 215 trials
Phase 2	NCT07511894	May 2026 → Dec 2027 expected	gastric cancer	Nanfang Hospital, Southern Medical University	Not yet recruiting	No outcome recorded
Phase 2	NCT04977180	Mar 2022 → Mar 2028 expected	acute myeloid leukemia	University of Virginia	Recruiting	No outcome recorded
Phase 2	NCT05198362	Dec 2021 → Dec 2022	Prader-Willi syndrome	Saniona	Withdrawn	No outcome recorded
Phase 2	NCT04562116	Dec 2021 → Jun 2023	atopic eczema	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT04633005	Nov 2021 → Oct 2025	heart failure	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 2	NCT05147415	Nov 2021 → Dec 2022	acquired hypothalamic obesity	Saniona	Withdrawn	No outcome recorded
Phase 2	NCT03845075	Feb 2019 → Oct 2020	acquired hypothalamic obesity	Saniona	Completed	No outcome recorded
Phase 2	NCT03696758	Oct 2018 → Feb 2020	pulmonary immaturity	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 2	NCT03070184	Apr 2017 → Dec 2023	hypertensive disorder	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 2	NCT03149445	Mar 2017 → Jul 2019	Prader-Willi syndrome	Saniona	Completed	No outcome recorded
Phase 2	NCT02737891	Apr 2016 → Jan 2017	type 2 diabetes mellitus	Saniona	Completed	No outcome recorded
Phase 2	NCT01434134	Sep 2011 → Sep 2014	breast cancer, heart failure	University Hospital, Akershus	Completed	No outcome recorded
Phase 2	NCT03882710	Jan 2010 → Oct 2012	diastolic heart failure	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2	NCT00302692	Dec 2005 → Sep 2008	cardiovascular disorder	University of Texas Southwestern Medical Center	Unknown	No outcome recorded
Phase 2	NCT00000499	Sep 1980 → May 1983	heart disorder, hypertensive disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT07268170	Dec 2025 → Sep 2028 expected	coronary artery disorder, ischemic disease	Gødstrup Hospital	Enrolling by invitation	No outcome recorded
Phase 2/3	NCT02408172	Oct 2013 → Jun 2017	hypertensive disorder, obstructive sleep apnea syndrome	First Affiliated Hospital of Harbin Medical University	Unknown	No outcome recorded
Phase 313 trials
Phase 3	NCT05631730	Jan 2023 → Jun 2026 overdue	cardiac rhythm disease, mitral valve prolapse	Oslo University Hospital	Recruiting	No outcome recorded
Phase 3	NCT05066633	Aug 2021 → Jun 2023	Duchenne muscular dystrophy	Medical University of Gdansk	Unknown	No outcome recorded
Phase 3	NCT04980716	Jun 2021 → Jan 2026 overdue	non-small cell lung carcinoma	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 3	NCT03541109	May 2019 → Aug 2023	ST-elevation myocardial infarction	Isfahan University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT02269696	Mar 2018	breast cancer	Kuopio University Hospital	Withdrawn	No outcome recorded
Phase 3	NCT03138603	Dec 2016 → Apr 2023	heart disorder	University of Chicago	Completed	No outcome recorded
Phase 3	NCT00077948	Jul 2003 → Jun 2005	congestive heart failure	Gilead Sciences	Terminated	No outcome recorded
Phase 3	NCT00642096	Jun 2003 → Jul 2004	essential hypertension	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00182039	Oct 2002 → Jul 2007	cardiovascular disorder	Hamilton Health Sciences Corporation	Terminated	No outcome recorded
Phase 3	NCT00255528	Jul 2002 → ?	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00255502	Jul 2002 → ?	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00038077	Aug 2001 → Sep 2003	congestive heart failure	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT04364139	Feb 1995 → Sep 2001	chronic kidney disease, nephrosclerosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded

Phase 445 trials
Phase 4	NCT07490067	Jul 2026 → Jul 2029 expected	symptomatic heart failure	University of Michigan	Recruiting	No outcome recorded
Phase 4	NCT07597564	Jun 2026 → May 2027 expected	—	Fujian Provincial Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07240909	Jan → Dec 2026 expected	hypertensive disorder	The Third Xiangya Hospital of Central South University	Not yet recruiting	No outcome recorded
Phase 4	NCT06825728	Feb 2025 → Feb 2028 expected	chronic obstructive pulmonary disease, systolic heart failure	Xiangya Hospital of Central South University	Not yet recruiting	No outcome recorded
Phase 4	NCT06569212	Sep 2024 → Sep 2026 expected	subarachnoid hemorrhage	Madeleine Puissant	Recruiting	No outcome recorded
Phase 4	NCT06035978	Mar 2024 → Apr 2026	symptomatic heart failure	University Hospital Ostrava	Unknown	No outcome recorded
Phase 4	NCT06357104	Feb → Mar 2024	—	Pachankis, Yang I., M.D.	Completed	No outcome recorded
Phase 4	NCT05585125	Feb 2024 → Jul 2026 overdue	diastolic heart failure	Weill Medical College of Cornell University	Enrolling by invitation	No outcome recorded
Phase 4	NCT05019027	Jan 2024 → Mar 2026 overdue	amyloidosis, heart disorder	Weill Medical College of Cornell University	Enrolling by invitation	No outcome recorded
Phase 4	NCT05711810	Jan 2023	Orthocoronavirinae infectious disease, myocarditis	Yang I. Pachankis	Completed	No outcome recorded
Phase 4	NCT05637853	Oct 2022 → Aug 2024 overdue	symptomatic heart failure	Göteborg University	Active not recruiting	No outcome recorded
Phase 4	NCT05377203	Jul 2022 → Jul 2023	hypertensive disorder	The Third Xiangya Hospital of Central South University	Completed	No outcome recorded
Phase 4	NCT04234477	Dec 2021 → Jun 2022	atrial fibrillation	Boston University	Withdrawn	No outcome recorded
Phase 4	NCT04133532	Mar 2020 → Feb 2023	hypertrophic cardiomyopathy	University Hospital, Motol	Completed	No outcome recorded
Phase 4	NCT03778554	Dec 2018 → Apr 2025 overdue	ST-elevation myocardial infarction	Bispebjerg Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT03596385	Oct 2018 → Jan 2025	myocardial infarction	National Center for Cardiovascular Research Carlos III	Completed	No outcome recorded
Phase 4	NCT03278509	Sep 2017 → Nov 2023	ST-elevation myocardial infarction	Karolinska Institutet	Unknown	No outcome recorded
Phase 4	NCT03008382	Mar 2017 → Mar 2022	interstitial cystitis, myofascial pain syndrome	Virginia Commonwealth University	Completed	No outcome recorded
Phase 4	NCT02251509	Dec 2016 → Sep 2017	atrial fibrillation	Creighton University	Unknown	No outcome recorded
Phase 4	NCT02924454	Sep 2016 → Mar 2017	hypertensive disorder	Mikkel Bring Christensen	Completed	No outcome recorded
Phase 4	NCT02746575	Nov 2015 → Oct 2016	intrinsic cardiomyopathy	Washington University School of Medicine	Completed	No outcome recorded
Phase 4	NCT01755663	Dec 2014	coronary artery disorder	Col. Suthee Panichkul	Unknown	No outcome recorded
Phase 4	NCT05008250	Jan 2014 → Aug 2015	cardiac rhythm disease	Xuanwu Hospital, Beijing	Completed	No outcome recorded
Phase 4	NCT02025465	Dec 2013 → Dec 2018	atrial fibrillation, atrial flutter	CAMC Health System	Unknown	No outcome recorded
Phase 4	NCT01605370	Jun 2012 → Mar 2013	hypertensive disorder	Mayo Clinic	Terminated	No outcome recorded
Phase 4	NCT01595516	Feb 2012 → Oct 2017	hypertensive disorder	University of Colorado, Boulder	Completed	No outcome recorded
Phase 4	NCT01655303	Feb → Dec 2011	atrial fibrillation	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT00992056	Dec 2010 → Feb 2012	hypertensive disorder	University of Miami	Completed	No outcome recorded
Phase 4	NCT01213173	Oct 2010 → Sep 2011	—	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01203852	Aug 2010 → Apr 2014	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT00999102	Oct 2009 → Jan 2011	hypertensive disorder	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT00819104	Nov 2008 → Aug 2009	essential hypertension	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01029223	Oct 2008 → Dec 2011	hypertensive disorder	Bayside Health	Withdrawn	No outcome recorded
Phase 4	NCT00885651	Sep 2008 → Aug 2009	heart failure	Rigshospitalet, Denmark	Unknown	No outcome recorded
Phase 4	NCT00491387	Aug 2007 → Jan 2009	hypertensive disorder	University of Cincinnati	Terminated	No outcome recorded
Phase 4	NCT00241904	May 2006 → May 2010	atherosclerosis, coronary artery disorder, diabetes mellitus, hypertensive disorder +1	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00288548	Feb 2006 → ?	chronic obstructive pulmonary disease	Martini Hospital Groningen	Unknown	No outcome recorded
Phase 4	NCT00861016	Oct 2005 → Apr 2006	essential hypertension	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01917149	Mar 2005 → Jul 2013	dilated cardiomyopathy	Xijing Hospital	Completed	No outcome recorded
Phase 4	NCT00166400	Jul 2004 → Jul 2007	heart valve disorder	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT03370835	Jun 2004 → Jun 2008	asthma, chronic obstructive pulmonary disease	VA Greater Los Angeles Healthcare System	Completed	No outcome recorded
Phase 4	NCT00497003	Feb 2004 → Oct 2007	—	Bispebjerg Hospital	Completed	No outcome recorded
Phase 4	NCT00060931	Jun 2001 → Apr 2004	hypertensive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00060918	Jun 2001 → Apr 2004	hypertensive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00222573	Jul 1999 → Feb 2005	acute myocardial infarction	University of Oxford	Completed	No outcome recorded

Phase not applicable23 trials
—	NCT07519161	Apr 2026 → Dec 2029 expected	atrial fibrillation	Shanghai East Hospital	Not yet recruiting	No outcome recorded
—	NCT07099677	Aug 2025 → Jun 2026 overdue	essential hypertension	Abant Izzet Baysal University	Recruiting	No outcome recorded
—	NCT07568873	Jan → Dec 2024	—	Zagazig University	Completed	No outcome recorded
—	NCT05741385	Oct 2023 → Aug 2024	cirrhosis of liver	Boehringer Ingelheim	Completed	No outcome recorded
—	NCT07074834	Feb 2021 → Sep 2022	coronary artery disorder	Shiyan City Renmin Hospital	Completed	No outcome recorded
—	NCT04513509	Oct 2020 → Jun 2022	atrial fibrillation	National Taiwan University Hospital	Completed	No outcome recorded
—	NCT04221919	Jan 2020 → Jan 2021	strictly posterior acute myocardial infarction	Qilu Hospital of Shandong University	Unknown	No outcome recorded
—	NCT03337945	Apr 2018 → Jun 2021	cirrhosis of liver	University Hospital, Basel, Switzerland	Completed	No outcome recorded
—	NCT03413410	Feb 2018 → Jul 2019	acute coronary syndrome	Yun Dai Chen	Unknown	No outcome recorded
—	NCT03579914	Nov 2017 → Aug 2020	heart failure, myocardial infarction	Harbin Medical University	Completed	No outcome recorded
—	NCT02248753	Oct 2014 → Nov 2018	atrial fibrillation	Maastricht University Medical Center	Completed	No outcome recorded
—	NCT02293096	Sep 2014 → Aug 2017	hypertensive disorder	University of Colorado, Denver	Terminated	No outcome recorded
—	NCT01658657	Oct 2012 → Jul 2014	hypertensive disorder, proteolytic capacity of plasma	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT01544959	Jan 2010 → Jan 2013	breast cancer	University of Sherbrooke	Completed	No outcome recorded
—	NCT01051947	Dec 2009 → May 2010	—	Creighton University	Withdrawn	No outcome recorded
—	NCT00995072	Oct 2009 → Apr 2013	hypertensive disorder, sexual disorder	East Coast Institute for Research	Completed	No outcome recorded
—	NCT00849810	Jan 2009 → Nov 2010	hypertensive disorder	University of Mississippi Medical Center	Terminated	No outcome recorded
—	NCT00627861	Nov 2008 → May 2010	hypertensive disorder	The Rogosin Institute	Terminated	No outcome recorded
—	NCT00756236	Oct 2008 → Sep 2015	myocardial ischemia	University of Oklahoma	Completed	No outcome recorded
—	NCT00578617	Sep 2006 → Feb 2009	atrial fibrillation	Mayo Clinic	Completed	No outcome recorded
—	NCT00214318	Jan 2005 → Feb 2007	heart failure	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00198614	Jan 2005 → ?	atrial fibrillation, coronary artery disorder	Ministry of Health, Labour and Welfare, Japan	Completed	No outcome recorded
—	NCT00475462	Jul 2001 → Dec 2003	syncope, familial vasovagal	Peking University First Hospital	Completed	No outcome recorded

Also used as a comparator or background therapy in 135 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02029118 Background	Oct 2012 → May 2015	—	Chengdu University of Traditional Chinese Medicine	Completed	No outcome recorded
Phase 19 trials
Phase 1	NCT01523002 Comparator	Jan → Jul 2012	malaria	Medicines for Malaria Venture	Completed	No outcome recorded
Phase 1	NCT01337674 Background	Apr → Nov 2011	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01187862 Background	Jul 2010 → Feb 2011	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT00648050 Comparator	Mar 2006	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT02264002 Comparator	Feb → Nov 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00649233 Comparator	Jan → Feb 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649688 Comparator	Jan → Feb 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649116 Comparator	Dec 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT01523054 Comparator	Feb 2000 → Apr 2002	acute myocardial infarction	AstraZeneca	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT03384524 Comparator	Mar 2018 → May 2019	diabetic macular edema	Andrew Moshfeghi, MD, MBA	Withdrawn	No outcome recorded
Phase 1/2	NCT05768542 Comparator	Apr 2016 → Mar 2022	Tako-tsubo cardiomyopathy	Danderyd Hospital	Completed	No outcome recorded
Phase 211 trials
Phase 2	NCT05546320 Comparator	Oct 2022 → Mar 2025	migraine disorder, patent foramen ovale	Chinese Academy of Medical Sciences, Fuwai Hospital	Completed	No outcome recorded
Phase 2	NCT06592547 Comparator	Apr 2022 → Dec 2023	infectious disease with sepsis	Alexandria University	Completed	No outcome recorded
Phase 2	NCT03532802 Comparator	May 2018 → Sep 2020	hypertrophic cardiomyopathy	Steen Hvitfeldt Poulsen	Completed	No outcome recorded
Phase 2	NCT02966717 Comparator	Aug → Oct 2016	chronic kidney disease, nephrotic syndrome	Zhujiang Hospital	Unknown	No outcome recorded
Phase 2	NCT01970501 Comparator	Apr 2014 → Dec 2017	atrial fibrillation	ARCA Biopharma, Inc.	Completed	No outcome recorded
Phase 2	NCT02076711 Comparator	Jun 2013 → Sep 2015	aortic valve stenosis	Aarhus University Hospital	Completed	No outcome recorded
Phase 2	NCT01901549 Comparator	Jun 2013 → Jun 2015	acute coronary syndrome, hypertensive disorder	Meshalkin Research Institute of Pathology of Circulation	Unknown	No outcome recorded
Phase 2	NCT00993421 Comparator	Oct 2009 → Jun 2010	obesity disorder	Eli Lilly and Company	Terminated	No outcome recorded
Phase 2	NCT00865917 Comparator	Nov 2008 → Nov 2010	postural orthostatic tachycardia syndrome	Hannover Medical School	Unknown	No outcome recorded
Phase 2	NCT00605072 Background	Jan 2008 → Dec 2011	cognitive impairment with or without cerebellar ataxia, hypertensive disorder	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00401882 Comparator	Jan 2007 → Jun 2011	cardiac arrest, sudden cardiac arrest, ventricular fibrillation, ventricular tachycardia	David Haines, MD	Terminated	No outcome recorded

Phase 2/37 trials
Phase 2/3	NCT03162120 Comparator	Sep → Dec 2018	atrial fibrillation	Elpen Pharmaceutical Co. Inc.	Withdrawn	No outcome recorded
Phase 2/3	NCT02772354 Comparator	Apr 2016 → Sep 2017	cardiac rhythm disease	Meshalkin Research Institute of Pathology of Circulation	Unknown	No outcome recorded
Phase 2/3	NCT02513927 Comparator	Aug 2015 → Oct 2017	essential hypertension	First Affiliated Hospital of Harbin Medical University	Unknown	No outcome recorded
Phase 2/3	NCT01863173 Comparator	Jan → May 2012	beta thalassemia	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT00829296 Comparator	Jan 2009 → Apr 2012	hypertensive disorder, type 2 diabetes mellitus	University of Chicago	Completed	No outcome recorded
Phase 2/3	NCT00152633 Comparator	Sep 2005 → Jan 2006	hypertensive disorder	University of Erlangen-Nürnberg Medical School	Withdrawn	No outcome recorded
Phase 2/3	NCT01052428 Comparator	Aug 2004 → Jul 2010	mitral valve insufficiency	University of Alabama at Birmingham	Completed	No outcome recorded

Phase 318 trials
Phase 3	NCT05847517 Comparator	Jul 2024 → Oct 2025	acute respiratory distress syndrome	Biomedical Research Networking Center (CIBER)	Terminated	No outcome recorded
Phase 3	NCT05931276 Comparator	May 2024 → Dec 2026 expected	end stage renal failure	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 3	NCT05767346 Comparator	Jun 2023 → Feb 2025	hypertrophic cardiomyopathy	Cytokinetics	Completed	No outcome recorded
Phase 3	NCT03689946 Background	Mar 2019 → Jan 2023	cardiovascular disorder, hyperlipidemia	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 3	NCT02587351 Comparator	May 2016 → Sep 2019	chronic obstructive pulmonary disease	University of Minnesota	Terminated	No outcome recorded
Phase 3	NCT02012075 Comparator	Dec 2013 → Feb 2015	heart failure	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT01970059 Comparator	Oct 2013	essential hypertension	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT01676285 Comparator	Jan 2012 → Sep 2013	cirrhosis of liver, cirrhotic cardiomyopathy	University of Sao Paulo	Completed	No outcome recorded
Phase 3	NCT01499134 Comparator	Aug 2011 → Jun 2014	hypertensive disorder, peripheral arterial disease	Thomas Jefferson University	Completed	No outcome recorded
Phase 3	NCT00953212 Comparator	Aug 2009 → Jan 2012	atrial fibrillation, atrial flutter	MaineHealth	Completed	No outcome recorded
Phase 3	NCT01281787 Comparator	Apr 2008 → Jun 2013	atrial fibrillation, lung cancer	European Institute of Oncology	Completed	No outcome recorded
Phase 3	NCT00589303 Comparator	Dec 2007 → Jul 2011	atrial fibrillation, heart failure	Mayo Clinic	Terminated	No outcome recorded
Phase 3	NCT00313157 Comparator	Apr 2006 → Sep 2010	atrial fibrillation	Asker & Baerum Hospital	Completed	No outcome recorded
Phase 3	NCT00273052 Comparator	Jan 2006 → Dec 2007	hypertensive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00142584 Comparator	Aug 2005 → Mar 2008	hypertensive disorder	Mylan Bertek Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00942487 Comparator	Apr 2005 → Dec 2008	essential hypertension	Berlin-Chemie Menarini	Completed	No outcome recorded
Phase 3	NCT00679653 Comparator	Feb 2002 → Dec 2003	hypertensive disorder, obesity disorder	Abbott	Completed	No outcome recorded
Phase 3	NCT00000620 Background	Sep 1999 → Jun 2009	atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 463 trials
Phase 4	NCT07706075 Comparator	Jan → Jul 2027 expected	atrial fibrillation	Muhammad Ali Javed	Not yet recruiting	No outcome recorded
Phase 4	NCT07445789 Comparator	Jun 2026 → Jun 2029 expected	atrial fibrillation	Martini Hospital Groningen	Not yet recruiting	No outcome recorded
Phase 4	NCT07298993 Comparator	Feb 2026 → Apr 2029 expected	heart failure	Weill Medical College of Cornell University	Enrolling by invitation	No outcome recorded
Phase 4	NCT07103655 Background	Jan → Jul 2026 overdue	hypertrophic cardiomyopathy	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 4	NCT07238452 Comparator	Dec 2025 → Dec 2032 expected	atrial fibrillation, symptomatic heart failure	University of British Columbia	Not yet recruiting	No outcome recorded
Phase 4	NCT06964464 Comparator	Aug 2025 → Jun 2031 expected	cardiomyopathy, sudden cardiac arrest, systolic heart failure	University of Rochester	Recruiting	No outcome recorded
Phase 4	NCT04914234 Comparator	Aug 2025 → Jan 2026 overdue	hypotensive disorder	Damanhour Teaching Hospital	Recruiting	No outcome recorded
Phase 4	NCT06864234 Comparator	Jul → Dec 2025 overdue	coronary artery disorder	VZW Cardiovascular Research Center Aalst	Recruiting	No outcome recorded
Phase 4	NCT06371222 Comparator	Feb 2023 → Jan 2024	mitral valve stenosis	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Completed	No outcome recorded
Phase 4	NCT04457323 Comparator	Jan → Oct 2022	hypertensive disorder	Neutec Ar-Ge San ve Tic A.Ş	Unknown	No outcome recorded
Phase 4	NCT04434664 Comparator	Dec 2021 → Dec 2024	diastolic heart failure, hypertensive disorder	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT04757584 Comparator	Apr 2021 → Apr 2023	diastolic heart failure	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT04767061 Comparator	Apr 2021 → Apr 2022	diastolic heart failure	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT05368376 Comparator	Apr 2021 → Oct 2022	hypotensive disorder	Damanhour Teaching Hospital	Completed	No outcome recorded
Phase 4	NCT04661709 Background	Mar 2021 → Mar 2023	intermediate coronary syndrome	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT05261464 Comparator	Jan 2021 → Jun 2022	—	Mahidol University	Unknown	No outcome recorded
Phase 4	NCT04575675 Background	May → Nov 2020	heart failure, hypotensive disorder	Cheng-Hsin General Hospital	Completed	No outcome recorded
Phase 4	NCT03895411 Background	Aug 2019 → Dec 2020	cardiac rhythm disease	Shengjing Hospital	Unknown	No outcome recorded
Phase 4	NCT04049786 Comparator	Jun 2019 → Aug 2022	obesity disorder	Natalia Valadares de Moraes	Unknown	No outcome recorded
Phase 4	NCT03646357 Comparator	Oct 2018 → Apr 2025 overdue	ST-elevation myocardial infarction	Oslo University Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT03566667 Comparator	Jun 2018 → Dec 2025 overdue	chronic obstructive pulmonary disease	Ole Frobert, MD, PhD	Active not recruiting	No outcome recorded
Phase 4	NCT07405229 Comparator	May 2018 → Dec 2032 expected	cardiac arrest, ventricular fibrillation	Bo Gregers Winkel	Recruiting	No outcome recorded
Phase 4	NCT03072121 Background	Jun 2017 → Dec 2018	coronary artery disorder	Jun Li	Unknown	No outcome recorded
Phase 4	NCT03072082 Background	Jun 2017 → Dec 2018	coronary artery disorder	Jun Li	Unknown	No outcome recorded
Phase 4	NCT02809820 Comparator	May → Dec 2016	acute coronary syndrome	Federico II University	Completed	No outcome recorded
Phase 4	NCT02695992 Comparator	Feb 2016 → Oct 2021	atrial fibrillation	Asker & Baerum Hospital	Completed	No outcome recorded
Phase 4	NCT02767401 Comparator	Sep 2015 → Aug 2018	arterial occlusion, myocardial stunning	The First Affiliated Hospital of Dalian Medical University	Completed	No outcome recorded
Phase 4	NCT02612298 Comparator	Aug 2015 → Sep 2018	essential hypertension	Marubeni Pharmaceuticals (Suzhou) Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT02417246 Comparator	Aug 2015 → Jun 2018	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT02484859 Comparator	Jul → Dec 2015	nasal cavity polyp	Recep Tayyip Erdogan University	Completed	No outcome recorded
Phase 4	NCT02123056 Comparator	Oct 2014 → Mar 2021	syncope, familial vasovagal	University of Calgary	Unknown	No outcome recorded
Phase 4	NCT02200822 Comparator	Jul 2014 → Feb 2019	heart failure	Hasselt University	Completed	No outcome recorded
Phase 4	NCT01837069 Comparator	Feb 2014 → Apr 2018	cardiovascular disorder, osteoarthritis	NYU Langone Health	Terminated	No outcome recorded
Phase 4	NCT01508325 Comparator	Dec 2011 → Apr 2014	essential hypertension	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 4	NCT01500590 Comparator	Nov 2011 → Aug 2018	hypertensive disorder, type 2 diabetes mellitus	Hospital Authority, Hong Kong	Unknown	No outcome recorded
Phase 4	NCT01395329 Comparator	May 2011 → Nov 2016	hypertensive disorder	University of Colorado, Boulder	Completed	No outcome recorded
Phase 4	NCT01404767 Comparator	Apr 2011	heart disorder, hypertensive disorder	University Health Network, Toronto	Terminated	No outcome recorded
Phase 4	NCT01311700 Comparator	Nov 2010 → Oct 2012	myocardial infarction	National Center for Cardiovascular Research Carlos III	Completed	No outcome recorded
Phase 4	NCT03635125 Comparator	Aug 2010 → May 2011	—	Trinity Hypertension & Metabolic Research Institute	Completed	No outcome recorded
Phase 4	NCT01157572 Comparator	Aug 2010 → Aug 2014	aortic valve insufficiency	Oslo University Hospital	Completed	No outcome recorded
Phase 4	NCT01501929 Comparator	Aug 2010 → Dec 2015	hypertensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT01157234 Comparator	Jul 2010 → Jul 2014	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT01049009 Comparator	Dec 2009 → Jun 2012	hypertensive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01041287 Comparator	Dec 2009 → Dec 2013	hypertensive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT01914926 Comparator	Jun 2009 → Nov 2010	cardiac rhythm disease	Antonios Likourezos	Completed	No outcome recorded
Phase 4	NCT01502787 Comparator	Apr 2009 → Jun 2013	hypertensive disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00825123 Comparator	Oct 2008 → Nov 2011	—	Bayside Health	Terminated	No outcome recorded
Phase 4	NCT00775671 Comparator	Oct 2008 → Jun 2011	metabolic syndrome X	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT00806390 Comparator	Jul 2008 → Jun 2012	cardiomyopathy	University of Maryland, Baltimore	Terminated	No outcome recorded
Phase 4	NCT01238705 Comparator	Apr 2008 → Oct 2010	essential hypertension, sexual disorder	LanZhou University	Unknown	No outcome recorded
Phase 4	NCT00732511 Comparator	Apr → Dec 2008	diabetes mellitus, hypertensive disorder	State University of New York - Downstate Medical Center	Unknown	No outcome recorded
Phase 4	NCT00784316 Comparator	Aug 2007 → Jul 2009	atrial fibrillation	Kuopio University Hospital	Completed	No outcome recorded
Phase 4	NCT00433043 Comparator	Jan 2007 → May 2009	congestive heart failure	St. Luke's-Roosevelt Hospital Center	Terminated	No outcome recorded
Phase 4	NCT00391846 Background	Oct 2006 → Jan 2009	left ventricular failure	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01458600 Background	Sep 2006 → Feb 2016	Graves disease	Mikael Lantz	Completed	No outcome recorded
Phase 4	NCT01248338 Comparator	Mar 2006 → Dec 2008	hypertensive disorder	Berlin-Chemie Menarini	Completed	No outcome recorded
Phase 4	NCT00661895 Background	Aug 2005 → Aug 2009	hypertensive disorder	Creighton University	Completed	No outcome recorded
Phase 4	NCT00384566 Comparator	Jun 2005 → Apr 2008	chronic obstructive pulmonary disease, heart failure	The Alfred	Withdrawn	No outcome recorded
Phase 4	NCT00123604 Comparator	Jun 2004 → Jun 2006	essential hypertension, type 2 diabetes mellitus	St. Paul Heart Clinic	Completed	No outcome recorded
Phase 4	NCT00642434 Comparator	Jan 2004 → Jun 2008	type 2 diabetes mellitus	University of New Mexico	Completed	No outcome recorded
Phase 4	NCT02242812 Comparator	Sep 2003 → Oct 2004	hypertensive disorder	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT01798992 Comparator	Sep 2000 → Mar 2009	non-familial dilated cardiomyopathy	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT00718406 Comparator	—	acute coronary syndrome	Sahlgrenska University Hospital	Completed	No outcome recorded

Phase not applicable24 trials
—	NCT07568574 Background	Mar 2026 → May 2028 expected	—	Enhanced Emirates Limited	Enrolling by invitation	No outcome recorded
—	NCT07445334 Comparator	Mar 2026 → Sep 2027 expected	cardiac rhythm disease	Western Sydney Local Health District	Not yet recruiting	No outcome recorded
—	NCT07335900 Background	Dec 2025 → Dec 2026 expected	aortic valve stenosis	RenJi Hospital	Recruiting	No outcome recorded
—	NCT06967194 Comparator	May 2025 → May 2027 expected	ST-elevation myocardial infarction, cardiogenic shock	Tel-Aviv Sourasky Medical Center	Recruiting	No outcome recorded
—	NCT05690737 Comparator	Sep 2023 → Dec 2025 overdue	migraine disorder	The Hong Kong Polytechnic University	Recruiting	No outcome recorded
—	NCT07378228 Background	Jul 2023 → Jun 2024	coronary artery disorder	Xikun Li	Completed	No outcome recorded
—	NCT07130175 Background	Dec 2022 → Dec 2024	heart failure, polymorphic ventricular tachycardia	Qian Feng	Completed	No outcome recorded
—	NCT04744571 Background	Feb 2021 → Dec 2022	arterial occlusion, coronary artery disorder	Beijing Anzhen Hospital	Unknown	No outcome recorded
—	NCT03830957 Comparator	Nov 2018 → Dec 2019	advanced heart failure, cardiomyopathy, diastolic heart failure, systolic heart failure	Rajaie Cardiovascular Medical and Research Center	Unknown	No outcome recorded
—	NCT03504956 Background	Jul 2018 → Dec 2025 overdue	coronary atherosclerosis	Cedars-Sinai Medical Center	Recruiting	No outcome recorded
—	NCT01686230 Background	Jul 2012 → Jul 2017	intermediate coronary syndrome	Chengdu University of Traditional Chinese Medicine	Completed	No outcome recorded
—	NCT01608893 Comparator	May 2012 → Jun 2025	atrial fibrillation	University of Calgary	Unknown	No outcome recorded
—	NCT01441570 Comparator	Feb 2012 → Jul 2013	hypertensive disorder	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT01117454 Background	Dec 2011 → Dec 2015	catecholaminergic polymorphic ventricular tachycardia	Vanderbilt University Medical Center	Completed	No outcome recorded
—	NCT01330654 Comparator	Mar 2011 → Mar 2012	—	University of California, San Francisco	Withdrawn	No outcome recorded
—	NCT01044693 Comparator	Jan 2010 → Jul 2014	hypertensive disorder, pure autonomic failure	Vanderbilt University	Completed	No outcome recorded
—	NCT00911508 Comparator	Nov 2009 → Dec 2017	atrial fibrillation	Mayo Clinic	Completed	No outcome recorded
—	NCT00563238 Comparator	Nov 2007 → Dec 2009	myocardial ischemia	Gregory A. Schmidt	Withdrawn	No outcome recorded
—	NCT00292162 Comparator	Jan 2007 → Jul 2009	atrial fibrillation, heart failure	NHS Greater Glasgow and Clyde	Completed	No outcome recorded
—	NCT00585871 Comparator	May 2006 → Jan 2012	ventricular tachycardia	James Martins	Withdrawn	No outcome recorded
—	NCT02336607 Comparator	Dec 2005 → Jun 2006	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
—	NCT00226096 Background	Nov 2005 → Sep 2007	intracerebral hemorrhage	The George Institute	Completed	No outcome recorded
—	NCT00745043 Comparator	May 2005 → Aug 2007	chronic obstructive pulmonary disease	Waikato Hospital	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 272 sources stand behind the page.

Field	Value	Cited text
Known as	metoprolol	“We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 2023 204 “Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗ “The betablocker given to the patient will be prioritized: 1) A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker:...” NCT07405229 ↗ “The first hypothesis of the study is that substituting fentanyl by esmolol and metoprolol during general anesthesia for patients undergoing mastectomy will result in less pain...” NCT01544959 ↗ “1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50...” NCT03286829 ↗ “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the...” NCT03504956 ↗ “amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily” NCT01500590 ↗ “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 “All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion.” NCT05637853 ↗ “Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration” NCT00942487 ↗ “IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.” NCT04234477 ↗ “Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg” NCT03635125 ↗ “If sotalol is contraindicated, an alternative BB may be initiated using standard doses (metoprolol, atenolol, bisoprolol).” NCT07445334 ↗ “Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis.” NCT05690737 ↗ “Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.” NCT01117454 ↗ “the plasma concentration and pharmacokinetic profile of a probe drug (IMP; metoprolol) released from IntelliCap®” NCT02025348 ↗ “betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol” NCT03596385 ↗ “This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.” NCT05198362 ↗ “fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)” NCT03541109 ↗ “Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.” NCT01686230 ↗ “representative drugs including bisoprolol, metoprolol sustained-release tablets, and carvedilol” NCT07335900 ↗ “Participants will receive a beta blocker (e.g., Metoprolol) for antihypertensive treatment.” NCT07099677 ↗ “High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally.” NCT07240909 ↗ “Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol” NCT04575675 ↗ “Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)” NCT04977180 ↗ “Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session.” NCT03361280 ↗ “Metoprolol 50 mg twice daily titrated to 100 mg twice daily” NCT01203852 ↗ “metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop” NCT02200822 ↗ “2. β receptor antagonist, metoprolol succinate 47.5mg qd” NCT04980716 ↗ “betaxolol, bisoprolol, metoprolol, nadolol, propranolol” NCT00684489 ↗ “metoprolol succinate sustained-release tablets 23.75mg” NCT05377203 ↗ “CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg)” PMID 39707077 ↗ Dec 2024 “Rate control: Metoprolol 50-100mg, Atenolol 50-100mg” NCT00911508 ↗ “metoprolol 25mg by mouth every 6 hours” NCT00953212 ↗ “* metoprolol * atenolol * carvedilol” NCT00589303 ↗ “Tesomet (tesofensine + metoprolol)” NCT05147415 ↗ “Daily metoprolol 95mg capsules” NCT00745043 ↗ “metoprolol (Toprol XL)” NCT00000620 ↗ “Metoprolol 50-100mg” NCT00578617 ↗ “Drug: Metoprolol” NCT00806390 ↗ “metoprolol/HCT” NCT00679653 ↗ “metoprolol” NCT04757584 ↗ “metoprolol” NCT06371222 ↗ “metoprolol” NCT04767061 ↗ NCT03103568 ↗ NCT05096884 ↗ NCT06967194 ↗ NCT00605072 ↗ NCT02924454 ↗ NCT06035978 ↗ NCT00756236 ↗ NCT01324388 ↗ NCT01404767 ↗ NCT02772354 ↗ NCT05767346 ↗ NCT03384524 ↗ NCT02336607 ↗ NCT01658657 ↗ NCT00993421 ↗ NCT05546320 ↗ NCT00999102 ↗ NCT02695992 ↗ NCT01902550 ↗ NCT03579914 ↗ NCT01970501 ↗ NCT02097511 ↗ NCT04425902 ↗ NCT02408172 ↗ NCT00000499 ↗ NCT00829296 ↗ NCT01901549 ↗ NCT01458600 ↗ NCT01029223 ↗ NCT02029118 ↗ NCT00241904 ↗ NCT02513927 ↗ NCT00849810 ↗ NCT00142584 ↗ NCT04457323 ↗ NCT04049786 ↗ NCT01585623 ↗ NCT03457597 ↗ NCT05891119 ↗ NCT07445789 ↗ NCT00292162 ↗ NCT01655303 ↗ NCT03689946 ↗ NCT01659944 ↗ NCT03441412 ↗ NCT03532802 ↗ NCT01330654 ↗ NCT03830957 ↗ NCT00223717 ↗ NCT05847517 ↗ NCT01970059 ↗ NCT05768542 ↗ NCT04434664 ↗ NCT00384566 ↗ NCT01523002 ↗ NCT06864234 ↗ NCT02269696 ↗ NCT01157572 ↗ NCT01863173 ↗ NCT00497003 ↗ NCT01187862 ↗ NCT02612298 ↗ NCT06357104 ↗ NCT00627861 ↗ NCT06569212 ↗ NCT00585871 ↗ NCT00222573 ↗ NCT04504045 ↗ NCT04364139 ↗ NCT03488719 ↗ NCT02737891 ↗ NCT00865917 ↗ NCT02647086 ↗ NCT02746575 ↗ NCT03162120 ↗ NCT04513509 ↗ NCT01157234 ↗ NCT00648271 ↗ NCT02123056 ↗ NCT02484859 ↗ NCT02248753 ↗ NCT01478490 ↗ NCT00401882 ↗ NCT01755663 ↗ NCT03008382 ↗ NCT01914926 ↗ NCT06825728 ↗ NCT00182039 ↗ NCT05368376 ↗ NCT01213173 ↗ NCT00825123 ↗ NCT00214318 ↗ NCT00302692 ↗ NCT07568574 ↗ NCT03278509 ↗ NCT00784316 ↗ NCT01051947 ↗ NCT05741385 ↗ NCT01238705 ↗ NCT01395329 ↗ NCT03845075 ↗ NCT03696758 ↗ NCT01508325 ↗ NCT00775671 ↗ NCT04082910 ↗ NCT01211821 ↗ NCT00313157 ↗ NCT07103655 ↗ NCT04914234 ↗ NCT00475462 ↗ NCT01837069 ↗ NCT07568873 ↗ NCT01608893 ↗ NCT03556592 ↗ NCT01523054 ↗ NCT00992056 ↗ NCT03566667 ↗ NCT00288548 ↗ NCT07597564 ↗ NCT00649233 ↗ NCT01845194 ↗ NCT01049009 ↗ NCT01434134 ↗ NCT01281787 ↗ NCT02940379 ↗ NCT04133532 ↗ NCT05631730 ↗ NCT00563238 ↗ NCT06808802 ↗ NCT00649116 ↗ NCT02025465 ↗ NCT06592547 ↗ NCT02417246 ↗ NCT00123604 ↗ NCT01917149 ↗ NCT01595516 ↗ NCT00885651 ↗ NCT07706075 ↗ NCT00060931 ↗ NCT02361619 ↗ NCT00152633 ↗ NCT00060918 ↗ NCT03413410 ↗ NCT01337674 ↗ NCT03882710 ↗ NCT03149445 ↗ NCT03070184 ↗ NCT02254148 ↗ NCT02772601 ↗ NCT06686628 ↗ NCT02293096 ↗ NCT00718406 ↗ NCT00642434 ↗ NCT02012075 ↗ NCT02809820 ↗ NCT01311700 ↗ NCT00198614 ↗ NCT01044693 ↗
Known as	Beloc	“Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets” NCT04457323 ↗
Known as	betaloc	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03895411 ↗ 2 NCT02767401 ↗ NCT04744571 ↗
Known as	Betaloc ZOK	“An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to...” NCT00861016 ↗ 3 “Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ “Name: Metoprolol Succinate Extended-Release Tablets (Brand Name: Betaloc® ZOK)” NCT07511894 ↗ “metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg” NCT02336607 ↗
Known as	Corvitol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00942487 ↗
Known as	ER metoprolol	“OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate (ER metoprolol) in children 6 to 16 years of...” PMID 17236889 ↗ Feb 2007
Known as	extended-release metoprolol succinate	“we randomly assigned 8351 patients with, or at risk of, atherosclerotic disease who were undergoing non-cardiac surgery to receive extended-release metoprolol succinate...” PMID 18479744 ↗ May 2008
Known as	Lopressor	“Metoprolol- Lopressor” NCT01523054 ↗ 1 NCT00649116 ↗
Known as	MET	“Drug: Metoprolol (MET)” NCT06967194 ↗ 3 “Metoprolol (MET)” NCT07597564 ↗ “Metoprolol (MET)” NCT00142584 ↗ “Metoprolol (MET)” NCT07568873 ↗
Known as	metoprolol (Toprol XL)	“metoprolol (Toprol XL)” NCT00000620 ↗
Known as	metoprolol CR	“oral metoprolol CR or matching placebo 100 mg” NCT00182039 ↗
Known as	metoprolol CR/XL	“This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and...” NCT00255528 ↗ 1 “A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A...” NCT00255502 ↗
Known as	metoprolol extended release	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00732511 ↗
Known as	metoprolol IR	“The purpose of this study is to evaluate effect of co-administration of JNJ-54452840 and metoprolol tartrate immediate-release (metoprolol IR) compared to metoprolol IR alone...” NCT01902550 ↗
Known as	Metoprolol is lopressor	“Metoprolol is lopressor” NCT00849810 ↗
Known as	Metoprolol succinate	“Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily)....” NCT07130175 ↗ 53 “we randomly assigned 8351 patients with, or at risk of, atherosclerotic disease who were undergoing non-cardiac surgery to receive extended-release metoprolol succinate...” PMID 18479744 ↗ May 2008 “Treatment with the beta-blocker metoprolol succinate in patients with asymptomatic moderate to severe AS has beneficial effects on LV myocardial oxidative metabolism,...” NCT02076711 ↗ “The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum...” NCT05096884 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol ...” NCT05019027 ↗ “In a double-blind, randomized, crossover study, 19 AA hypertensive patients were randomized to a 12-week treatment period with either nebivolol 10 mg or metoprolol succinate...” PMID 26285691 ↗ Aug 2015 “Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician.” NCT03278509 ↗ “Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks.” NCT01508325 ↗ “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ “Generic drug and accepted dosages will be: Metoprolol succinate up to a total dose of 200mg daily” NCT03646357 ↗ “evidence-based beta-blockers (extended-release metoprolol succinate, bisoprolol, carvedilol)” NCT07238452 ↗ “Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.” NCT04633005 ↗ “Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.” NCT02612298 ↗ “Name: Metoprolol Succinate Extended-Release Tablets (Brand Name: Betaloc® ZOK)” NCT07511894 ↗ “extended-release metoprolol succinate (Toprol-XL, AstraZeneca)” PMID 17576868 ↗ Jun 2007 “metoprolol succinate sustained-release tablets 23.75mg” NCT05377203 ↗ “Extended release Metoprolol succinate” NCT00819104 ↗ “Drug: Metoprololsuccinate” NCT02076711 ↗ “metoprolol succinate” NCT04757584 ↗ NCT02242812 ↗ NCT01501929 ↗ NCT01441570 ↗ NCT00391846 ↗ NCT05066633 ↗ NCT01676285 ↗ NCT07074834 ↗ NCT07378228 ↗ NCT00255502 ↗ NCT00255528 ↗ NCT01605370 ↗ NCT00491387 ↗ NCT03778554 ↗ NCT07490067 ↗ NCT07519161 ↗ NCT06964464 ↗ NCT01052428 ↗ NCT02264002 ↗ NCT00273052 ↗ NCT00433043 ↗ NCT00642096 ↗ NCT00861016 ↗ NCT01798992 ↗ NCT05745337 ↗ NCT01502787 ↗ NCT02587351 ↗ NCT00166400 ↗ NCT01248338 ↗ NCT01499134 ↗ NCT00995072 ↗ NCT00661895 ↗ NCT05711810 ↗ NCT01041287 ↗ NCT00077948 ↗ NCT05931276 ↗
Known as	Metoprolol succinate ER	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03370835 ↗
Known as	Metoprolol Succinate Extended-Release Tablets	“Drug: Metoprolol Succinate Extended-Release Tablets” NCT07378228 ↗
Known as	Metoprolol Sustained-Release Tablets	“High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally.” NCT07240909 ↗
Known as	metoprolol tartrate	“The purpose of this study is to evaluate effect of co-administration of JNJ-54452840 and metoprolol tartrate immediate-release (metoprolol IR) compared to metoprolol IR alone...” NCT01902550 ↗ 23 “CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ “Participants will be administered IV Metoprolol tartrate 15 mg (3 ampoules of 5 ml) diluted in 100 ml of saline.” NCT05847517 ↗ “Metoprolol tartrate will be provided to each patient randomized to the metoprolol group.” NCT00806390 ↗ “A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.” NCT03103568 ↗ “Metoprolol tartrate, target dose: 150 mg daily” NCT04221919 ↗ “metoprolol tartrate 50 mg single oral dose” NCT01044693 ↗ “Intravenous metoprolol tartrate” NCT06592547 ↗ “Drug: Metoprolol tartrate” NCT07706075 ↗ “metoprolol tartrate” NCT04757584 ↗ NCT02251509 ↗ NCT03138603 ↗ NCT05261464 ↗ NCT03072121 ↗ NCT03072082 ↗ NCT04661709 ↗ NCT05745337 ↗ NCT05008250 ↗ NCT00226096 ↗ NCT00649688 ↗ NCT07268170 ↗ NCT00661895 ↗
Known as	Metoprolol tartrate immediate-release	“The purpose of this study is to evaluate effect of co-administration of JNJ-54452840 and metoprolol tartrate immediate-release (metoprolol IR) compared to metoprolol IR alone...” NCT01902550 ↗
Known as	metoprolol tartrate IR	“Any potential interaction between JNJ-54452840 and metoprolol tartrate IR will primarily be evaluated by measuring exercise induced heart rate (that is, post exercise).” NCT01902550 ↗
Known as	Metoprolol XL	“Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.” NCT01049009 ↗
Known as	S-Metoprolol	“S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets” NCT04457323 ↗
Known as	Selo-Zok	“Drug: Metoprolole (Selo-Zok ®)” NCT00885651 ↗
Known as	TOPROL-XL	“This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and...” NCT00255528 ↗ 7 “A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A...” NCT00255502 ↗ “The three antihypertensive drug regimens contained either a calcium channel blocker (amlodipine), β-blocker (metoprolol; Toprol XL), or angiotensin-converting enzyme inhibitor...” NCT04364139 ↗ “whether Toprol xl, a beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation” NCT00700947 ↗ “mortality benefits (carvedilol \[Coreg\] 25 mg bid, metoprolol succinate \[Toprol-XL\] 200 mg qd)” NCT00433043 ↗ “metoprolol succinate (Toprol XL)” NCT01052428 ↗ “Metoprolol- Toprol XL” NCT01523054 ↗ NCT00700947 ↗
Known as	Verelan PM	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00648050 ↗
Action	Inhibit	“metoprolol, a conventional β1-selective antagonist” NCT00198614 ↗
Modality	Other / unclassified	“beta blocking agent (metoprolol)” NCT05768542 ↗
Route	Oral	“Metoprolol succinate administered orally” NCT00077948 ↗
Target	ADRB1	“Its selectivity for ADRB1 over ADRB2 allows it to precisely target the ADRB1 receptor highly expressed on CD8⁺ T cells” NCT07511894 ↗